Antibiotic resistance is on the rise and scientists are on the lookout for new therapeutics for treating human pathogens. One promising new venture repurposes antimalarial drugs to treat patients with chronic lung diseases such as cystic fibrosis.
AzurRx completes enrollment in Phase 2 clinical trial of MS1819 in combination with PERT to treat cystic fibrosis patients with severe exocrine pancreatic insufficiency
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.